Literature DB >> 33372040

Differential Regulation of Cancer Progression by CDK4/6 Plays a Central Role in DNA Replication and Repair Pathways.

Julien Boudreault1, Ni Wang1, Meiou Dai1, Sophie Poulet1, Girija Daliah1, Gang Yan1, Alaa Moamer1, Sergio A Burgos2,3, Siham Sabri1, Suhad Ali1, Jean-Jacques Lebrun4.   

Abstract

Although the cyclin-dependent kinases CDK4 and CDK6 play fundamental roles in cancer, the specific pathways and downstream targets by which they exert their tumorigenic effects remain elusive. In this study, we uncover distinct and novel functions for these kinases in regulating tumor formation and metastatic colonization in various solid tumors, including those of the breast, prostate, and pancreas. Combining in vivo CRISPR-based CDK4 and CDK6 gene editing with pharmacologic inhibition approaches in orthotopic transplantation and patient-derived xenograft preclinical models, we defined clear functions for CDK4 and CDK6 in facilitating tumor growth and progression in metastatic cancers. Transcriptomic profiling of CDK4/6 CRISPR knockouts in breast cancer revealed these two kinases to regulate cancer progression through distinct mechanisms. CDK4 regulated prometastatic inflammatory cytokine signaling, whereas CDK6 mainly controlled DNA replication and repair processes. Inhibition of CDK6 but not CDK4 resulted in defective DNA repair and increased DNA damage. Multiple CDK6 DNA replication/repair genes were not only associated with cancer subtype, grades, and poor clinical outcomes, but also facilitated primary tumor growth and metastasis in vivo. CRISPR-based genomic deletion of CDK6 efficiently blocked tumor formation and progression in preestablished cell- and patient-derived xenograft preclinical models of breast cancer, providing a potential novel targeted therapy for these deadly tumors. SIGNIFICANCE: In-depth transcriptomic analysis identifies cyclin-dependent kinases CDK4 and CDK6 as regulators of metastasis through distinct signaling pathways and reveals the DNA replication/repair pathway as central in promoting these effects. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33372040     DOI: 10.1158/0008-5472.CAN-20-2121

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.

Authors:  Meiou Dai; Gang Yan; Ni Wang; Girija Daliah; Ashlin M Edick; Sophie Poulet; Julien Boudreault; Suhad Ali; Sergio A Burgos; Jean-Jacques Lebrun
Journal:  Nat Commun       Date:  2021-05-24       Impact factor: 14.919

2.  The Immunological Role of CDK4/6 and Potential Mechanism Exploration in Ovarian Cancer.

Authors:  Chen Liu; Yuhan Huang; Yaoyuan Cui; Jun Zhou; Xu Qin; Li Zhang; Xi Li; Yuan Li; Ensong Guo; Bin Yang; Xi Li; Junpeng Fan; Xiong Li; Yu Fu; Si Liu; Dianxing Hu; Rourou Xiao; Zizhuo Wang; Yingyu Dou; Wei Wang; Wenting Li; Xiaohang Yang; Jingbo Liu; Wenju Peng; Tianyu Qin; Lixin You; Funian Lu; Chaoyang Sun
Journal:  Front Immunol       Date:  2022-01-14       Impact factor: 7.561

3.  Identification and Validation of Autophagy-Related Genes as Potential Biomarkers and Therapeutic Targets in Atrial Fibrillation.

Authors:  Jiao Zhou; Yunlong Dong; Xiang Cai; Hongbo Yang; Tao Guo
Journal:  Int J Gen Med       Date:  2021-11-06

4.  Circular RNA ERBIN Promotes Proliferation of Hepatocellular Carcinoma via the miR-1263/CDK6 Axis.

Authors:  Shikun Yang; Fei Yu; Yang Ji; Yanjun Shen; Hao Lu; Yuan Gao; Feng Zhang; Xuehao Wang; Chuanyong Zhang
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

5.  Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies.

Authors:  Miguel A Ortega; Leonel Pekarek; Oscar Fraile-Martinez; Cielo Garcia-Montero; Miguel A Saez; Angel Asúnsolo; Miguel A Alvarez-Mon; Jorge Monserrat; Lidia Ruiz-Llorente; Natalio García-Honduvilla; Agustin Albillos; Julia Buján; Melchor Alvarez-Mon; Luis G Guijarro
Journal:  Curr Oncol       Date:  2022-03-30       Impact factor: 3.109

Review 6.  Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas.

Authors:  Farinaz Barghi; Harlan E Shannon; M Reza Saadatzadeh; Barbara J Bailey; Niknam Riyahi; Khadijeh Bijangi-Vishehsaraei; Marissa Just; Michael J Ferguson; Pankita H Pandya; Karen E Pollok
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575

7.  A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.

Authors:  Chenchen Tian; Yufan Wei; Jianjun Li; Zhi Huang; Qiong Wang; Yingxue Lin; Xingping Lv; Yanan Chen; Yan Fan; Peiqing Sun; Rong Xiang; Antao Chang; Shuang Yang
Journal:  Int J Mol Sci       Date:  2022-03-07       Impact factor: 5.923

Review 8.  Targeting CDK4/6 for Anticancer Therapy.

Authors:  Jiating Qi; Zhuqing Ouyang
Journal:  Biomedicines       Date:  2022-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.